Investors

Investors

Founded in 2011 by ex-Pfizer R&D executives and healthcare entrepreneurs, Thetis Pharmaceuticals LLC is a biopharmaceutical company developing novel lipid-based drug candidates for the treatment of orphan gastrointestinal diseases with high unmet medical needs.


Our principal investor is Connecticut Innovations which has a long history of investing in the life sciences. Since 1995, Connecticut Innovations has invested over $98 million in more than 50 bioscience companies, including firms such as Achillion Pharmaceuticals (NasdaqGS:ACHN), Alexion Pharmaceuticals (NasdaqGS:ALXN), CGI Pharmaceuticals, Cara Therapeutics (NasdaqGM:CARA), CuraGen, Genaissance Pharmaceuticals, PRib-X Pharmaceuticals (nka:Melinta Therapeutics), Marinus Pharmaceuticals, New Haven Pharmaceuticals, CyVek, and Thetis Pharmaceuticals.

"We are committed to creating innovative products that improve the lives of patients suffering from rare GI diseases."